Purchase this article with an account.
A. Adan Civera, L. Pelegrin, R. Casaroli-Marano, C. Mateo, R. Navarro; Long-Term Safety and Efficacy of Intravitreal Bevacizumab (Avastin) as Primary Treatment for Inflammatory Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):64.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To asses the long-term effects of intravitreal bevacizumab as primary treatment in managing inflammatory choroidal neovascularization (CNV)
Sixteen consecutive patients with newly diagnosed inflammatory CNV treated with intravitreal injection of 1.25 mg of bevacizumab were reviewed retrospectively . Main outcome measure were : best corrected visual acuity , foveal thicknes measured by optical coherence tomography (OCT) and clinically completed resolution of CNV
CNV resolved completely in 16/16 (100%) affected eyes.At the last examination ,visual acuity was improved in 14 eyes (87,5%),stable in 2 (12,5%) , and worse in 0 (0 %) eyes. Over a mean follow-up of 16.5 months (range 10 to 31 months), twelve eyes received one injection ,three eyes developed CNV recurrence and requires a second injection and 1 eye requires a third injection. Foveal thickness on OCT images decreased significantly (p= 0.049 ) after the treatment .
In this small series of eyes with long-term follow-up , intravitreal bevacizumab for inflammatory CNV was found to be safe and showed favourable visual outcomes for both subfoveal and juxtafoveal or extrafoveal inflammatory CNV.
This PDF is available to Subscribers Only